Takeda is the world's 12th-largest pharmaceutical
company with market presence which spans
around 70 countries worldwide.

The network of the Takeda group spans around 70 countries worldwide, in Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific Region. Takeda's pharmaceutical products are marketed in around 100 countries worldwide, including partnerships (marketing alliance partners). Takeda ranks in 12th position in the world ranking for net sales of pharmaceutical companies.

Takeda's net sales by region (Fiscal 2011)

• Japan :

  733,400 million yen

• U.S. :

  464,400 million yen

• Europe :

  263,600 million yen

• Asia and Other Regions :

  47,500 million yen

• Business Activities

30,814 Employees Worldwide

30,814 employees worldwide

Takeda is accelerating development of talent with a global perspective and promotion of diversity; at the same time, building a sustainable organization by creating a work environment that allows employees to thrive and grow, as well as cultivating a corporate culture in which employees can resolutely tackle the challenge of drug discovery.

• Corporate Governance

We will fulfill our responsibility as a company committed to improving people's lives by continuing to globalize our organization and promote diversity.

Each Takeda Group company around the world conducts corporate citizenship activities in tandem with its business activities, working to tackle the issues faced by local communities and building partnerships with NGOs and NPOs.

• Global Community Involvement

An R&D-oriented global pharmaceutical company group with 17 R&D sites worldwide

Takeda aims to deliver medicines matching the various type of patients' needs through its efforts to strengthen the pipeline, which is achieved by maximizing our global presence in Europe, the Americas, Asia and Emerging Markets.

• R&D Organization

¥300 billion R&D expenses per year

Responding to the needs of patients is Takeda's greatest mission. In that spirit, we set our commitment to discovering and developing innovative pharmaceuticals that answer unmet medical needs.We are making strategic investments in a highly-prioritized pipeline of late-stage clinical trials, and working to maximize the efficiency of development costs.

• R&D Pipeline